Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specialized Risk Assessment

The legacy of general health and science information dissemination has long provided a foundation for public understanding of medication risks and benefits. Within this broad context, the focus on bone health and osteoporosis management has historically emphasized the role of bisphosphonates, such as Fosamax, in reducing fracture risk. As clinical evidence accumulated, attention shifted toward rare but serious adverse events, including osteonecrosis of the jaw (ONJ), particularly in patients undergoing dental procedures or with prolonged exposure. This evolving awareness represents a natural progression from general health education to more specialized risk assessment. In the occupational domain, the concern extends beyond patient populations to professionals who may encounter Fosamax exposure through manufacturing, handling, or administration. Workers in pharmaceutical production, healthcare settings, or dental practices face potential contact with the drug or its residues, raising questions about cumulative exposure and associated risks. The transition from a general health context to an occupational exposure concern thus pivots on recognizing that the same clinical evidence linking Fosamax to ONJ warrants scrutiny in workplace environments where repeated or high-level contact may occur. This shift does not presuppose mechanistic pathways but rather acknowledges the need for occupational health surveillance and exposure monitoring, grounded in the same evidence-based principles that inform patient care.

Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of necrotic bone that may be asymptomatic or associated with pain, infection, and delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis relies on clinical examination and imaging, with a focus on identifying exposed bone that persists for more than eight weeks in the absence of radiation therapy to the jaws. The jawbone's unique microarchitecture and cellular composition may contribute to its susceptibility to bisphosphonate-related complications, as multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanisms and Risk Factors for Fosamax-Associated ONJ

Fosamax pharmacology involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for increasing bone mass and reducing fracture risk, it can also impair the normal remodeling and repair processes in the jawbone. The accumulation of bisphosphonates in bone, particularly in areas of high turnover such as the jaws, may lead to oversuppression of bone turnover, microdamage accumulation, and compromised blood supply, ultimately predisposing to necrosis. Mechanistic pathways linking Fosamax to ONJ include the drug's long skeletal half-life, its concentration in the jawbone, and its effects on osteoclast function and angiogenesis. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ has been reported in patients taking bisphosphonates, including Fosamax, and the risk may increase with longer duration of use. For patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the label notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide guidance to healthcare providers and patients about the potential risk, though the label also indicates that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials may be low, and the condition can also occur spontaneously. Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and the development of ONJ, as well as the presence of other risk factors. The label notes that most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link in some cases. However, ONJ can also occur in patients not exposed to bisphosphonates, and the presence of other risk factors such as dental disease, cancer, or concomitant medications must be considered. The label emphasizes that the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), which is relevant for patients on long-term therapy. In summary, the clinical evidence supports a recognized association between Fosamax use and osteonecrosis of the jaw, with mechanistic plausibility and a variable timeline from exposure to harm. Warnings in the prescribing information address this risk, though the condition's multifactorial nature requires careful patient evaluation. For affected patients, consideration of drug discontinuation and management of dental risk factors are important steps.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that reduces bone turnover. This can impair jawbone remodeling and repair, leading to osteonecrosis of the jaw (ONJ). Clinical evidence shows an association, with risk increasing with longer use. The prescribing information includes warnings about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is Fosamax-associated ONJ diagnosed and managed?

Diagnosis is based on clinical exam and imaging showing exposed bone persisting >8 weeks without jaw radiation. Management includes drug discontinuation, dental care, and addressing risk factors. Most patients improve after stopping Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.